Tay Sook Muay is Associate Dean at the Yong Loo Lin School of Medicine at Singapore General Hospital. She is a senior consultant anaesthesiologist with a special interest in liver transplantation anaesthesiology, burns intensive care medicine and the psychology of learning and development. She is a highly experienced medical educator and has been the Lead Clinical Educator at Singapore General Hospital since 2012 . Her many education activities include being an ATLS Course Educator (Train the Trainers programme) and a facilitator for the 7 Habits programme at Singapore General Hospital. She also served as an Adjunct Associate Professor at the Office of Education, Duke NUS Graduate Medical School. Adj A/P Tay has published many papers on anaesthesiology and educational practice as well as co-authored in the book Anaesthesia for Emergency Medicine (World Scientific Publishing, 2004). She is currently involved in a variety of research projects examining clinician work practices and burns treatment. She is a member of many professional associations such as the Singapore Intensive Care Society, College of Anaesthesiologist, St John’s Order, Adult Education Network (AEN) and sat on committees such as the Pedagogy Committee at the Postgraduate Medical Institute and the Committee for Core Skills- Simulation Training Work. She has presented papers at a number of international conferences including the World Congress of Intensive Care Medicine, the ASME Conference and the Congress of the Western Pacific Association of Critical Care Medicine. Adj A/P Tay cares deeply about achieving the best possible outcomes for patients, as well as the resulting satisfaction and affirmation experienced by clinicians when this occurs. She firmly believes that this affirmative journey starts with the education of medical students on patient safety and best outcome.
Singapore General Hospital (SGH) is the first and largest hospital in Singapore. It provides affordable specialist care for patients, training for doctors and other healthcare professionals, and conducts research to bring better care to its patients. Every year, the SGH Campus caters to over 1 million patients. With a 10,000-strong workforce, SGH accounts for about a quarter of the total acute hospital beds in the public sector and about one-fifth of acute beds nationwide The Antimicrobial Stewardship Unit (ASU) in SGH is a multidisciplinary team, composed of Infectious Diseases Physicians, pharmacists and an executive who are responsible for directing complementary multi-pronged efforts to promote safe, optimal and cost-effective use of antimicrobials via several antimicrobial stewardship strategies. One of the strategies involves the prospective audit feedback of selected targeted broad-spectrum antimicrobials. Patients who are prescribed with targeted antimicrobials (e.g. carbapenems, piperacillin-tazobactam, IV ciprofloxacin and IV levofloxacin) are reviewed holistically by the ASU pharmacists. In the event where the antibiotic is inappropriately or sub-optimally prescribed, cases will be discussed with the ASU physician and suggestions given which typically include antimicrobial discontinuation when a bacterial infection is deemed less likely or when the infection has been adequately treated, de-escalation of antimicrobials to narrower- spectrum agents and IV-to-PO switch. The goal of antimicrobial stewardship is to reduce inappropriate antimicrobial use, improve patient care outcomes and minimize unintended consequences of antimicrobial use such as antimicrobial resistance, acquiring Clostridium difficile infections, unnecessary antimicrobial drug costs and antimicrobial-related complications.
Cuilian Sun has obtained her PhD from the National University of Singapore. She is currently the Deputy Laboratory Director of the Pharmaceutical Laboratory, at the Health Sciences Authority in Singapore. She leads the ASEAN Reference Substances Project and is actively involved in the development of western medicine monographs for the International Pharmacoepoeia fo the World Health Organisation (WHO).
Chinese medicinal materials (CMM) (also known as Chinese medicinal raw herbs) and Chinese proprietary medicines (CPM), being natural in nature, have been perceived by the public as relatively low risk. However, they are not completely free from the possibility of toxicity or other adverse effects. Potential harm can occur due to inherent toxic properties of the herbs, as well as contaminants or adulterants in CMM and CPM. Previously, various heavy metal surveys performed by the health authorities of China (in 2016) and Taiwan (in 2006) have indicated presence of high levels of arsenic in Cordyceps and high levels of cadmium in Bulbus Lilii. As China and Taiwan are major suppliers of CMM and CPM in Singapore, such findings in China and Taiwan raised safety concerns regarding raw and finished products of Cordyceps and Bulbus Lilii sold in Singapore. Hence, as a follow-up to a smaller pilot-study conducted in Singapore (2015/2016), a more extensive survey was carried out by the Pharmaceutical Laboratory of the Health Sciences Authority in 2017 to study the levels of arsenic, lead, mercury and cadmium present in 20 CMM samples of Cordyceps and Bulbus Lilii, as well as in 17 CPM samples containing these herbs retailed locally, using inductively-coupled plasma mass spectrometry (ICP-MS) technique. The results of this study are presented in this poster; these findings would be useful for facilitating the review of regulatory controls on toxic heavy metals in Chinese medicinal raw herbs and Chinese proprietary medicines, retailed in Singapore.